DIASENSOR COM INC
10-Q, 1999-08-13
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: GENERAL GROWTH PROPERTIES INC, 10-Q, 1999-08-13
Next: LEGG MASON GLOBAL TRUST INC, 497, 1999-08-13





             SECURITIES AND EXCHANGE COMMISSION

                   Washington, D.C.  20549


                          FORM 10-Q


     QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE
               SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended                  June 30, 1999

Commission file number             33-56574


                        DIASENSOR.COM
   (Exact name of registrant as specified in its charter)



Pennsylvania                                25-1605848
(State of other jurisdiction               (IRS Employer
of incorporation or organization)        Identification no.)


  2275 Swallow Hill Road, Bldg. 2500; Pittsburgh, PA 15220
(Address of principal executive offices)       ( Zip Code)

                       (412) 279-9740
     Registrant's telephone number, including area code

     Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by section 13 or
15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90
days.
                                   Yes   X        No

     As of June 30, 1999, 22,980,051 shares of
Diasensor.com, Inc. common stock, par value $.01 were
outstanding.

<PAGE>1

                                 DIASENSOR.COM, INC.
                         (A Development Stage Company)
                          Consolidated Balance Sheets

                                         June 30,     September 30,
 ASSETS                                    1999          1998
                                        (Unaudited)      (Note)
                                        -----------    -----------
Current assets
  Cash and cash equivalents (note A)    $   101,999    $   41,811
  Prepaid expenses                           20,563         5,792
                                        -----------    -----------
               Total current assets         122,562        47,603

Property and equipment - at cost (note A)
  Building and improvements                    -           222,296
  Furniture and fixtures                     42,750         42,750
                                        -----------    -----------
                                             42,750        265,046
  Less accumulated depreciation              26,804         69,553
                                        ------------   -----------
                                             15,946        195,493
                                        -----------    -----------
Other assets
  Due from BICO (note A)                  1,637,149      2,197,433
  Notes receivable-related parties            -            125,000
  Interest receivable-related parties         2,599          9,272
  Allowance for doubtful account         (1,639,748)    (2,282,479)
                                        -----------    -----------
                                              -             49,226
                                        -----------    -----------
               TOTAL ASSETS             $   138,508    $   292,322
                                        ===========    ===========

               LIABILITIES and STOCKHOLDERS' EQUITY

Current liabilities
  Accounts payable                      $     -        $    23,606
  Accrued payroll and withholdings           92,897         68,721
                                        -----------    -----------
           Total current liabilities         92,897         92,327

Stockholders' equity
  Preferred stock, 1,000,000 shares authorized, none issued
  Common stock, 40,000,000 shares of $.01 par value
  authorized; issued and outstanding
  22,980,051 at Sep. 30, 1998 and
  22,980,051 at June 30, 1999               229,801        229,801
  Additional paid-in capital             26,892,071     26,892,071
  Warrants                               17,953,223     17,953,223
  Deficit accumulated during the
  development stage                     (45,029,484)   (44,875,100)
                                        -----------    -----------
                                             45,611        199,995
               TOTAL LIABILITIES AND    -----------    -----------
                  STOCKHOLDERS' EQUITY  $   138,508    $   292,322
                                        ===========    ===========
[FN]
The accompanying notes are an integral part of this statement.

<PAGE>2
                             DIASENSOR.COM, INC.
                     (A Development Stage Company)

<TABLE>
                  Consolidated Statement of Operations
                              (Unaudited)
<CAPTION>
                                            For the six months ended         For the three months ended   From July 5, 1989
                                                     June 30,                          June 30,         (inception) through
                                              1999             1998            1999             1998       June 30, 1999
                                            -------------------------        --------------------------  -------------------
</CAPTION>
<S>                                      <C>              <C>              <C>              <C>            <C>
Research and development expenses        $        -       $      -       $        -        $      -       $ 10,556,405

General and administrative expenses            140,422        303,946         (102,067)        141,234      14,342,651

Warrant extensions                                -            25,000             -               -         17,912,908

Technology and patent rights acquired           49,857         13,080              620           7,580       2,698,172

Interest expense                                 1,499           -                -               -             12,028

Other income                                   (37,394)       (35,673)         (10,988)        (13,890)       (560,085)

Other expense                                     -               -                -              -             37,405
					    --------------------------	    --------------------------   -------------------
         Net loss                        $    (154,384)   $  (306,353)   $     112,435    $   (134,924)   $(44,999,484)
                                            ===========    ===========      ===========    ===========   ===================
Net loss per common share                $       (0.01)   $     (0.01)   $       (0.00)   $      (0.01)   $      (2.36)
                                            ===========    ===========      ===========    ===========   ===================

See notes to the financial statements.
</TABLE>
<PAGE>3
<TABLE>
                            DIASENSOR.COM, INC.
                     (A Development Stage Company)

                        Statement of Cash Flows
                              (Unaudited)


<CAPTION>

                                                       For the nine months ended   For the three months ended  From July 5,1989
                                                              June 30,                     June 30,            (Inception) thru
                                                        1999          1998            1999          1998         June 30, 1999
                                                       ------------------------   --------------------------  ----------------
 <S>                                             <C>             <C>            <C>           <C>           <C>
 Cash flows from operating activities
  Net Loss                                        $    (154,384)  $  (306,353)   $   112,435  $   (134,924)   $  (44,999,484)
  Adjustments to reconcile net loss to net
   cash used by operating activites:
    Depreciation                                        (42,749)        6,791          1,527         3,395            26,804
    Provision for doubtful accounts                         -              -             -            -            2,282,479
    Reduction inallowance for doubtful accounts        (505,916)           -        (469,580)         -             (505,916)
    Impairment loss                                         -              -             -            -               14,367
    Stock in exchange for services                          -              -             -            -              138,950
    Stock issued for License and Marketing Agreement        -              -             -            -               80,000
    Warrent extensions                                      -          25,000            -            -           17,912,908
    Inventory Deposit-BICO                                  -              -             -            -           (1,000,000)
    Decrease (Increase) in prepaid expenses             (14,771)        8,680         18,350         2,922           (20,563)
    Increase in payable due to BICO                         -              -             -            -           10,500,000
    Increase (Decrease) in accounts payable             (23,606)       22,439        (11,107)       23,559              -
    Increase (Decrease) in accrued liabilities           24,176           (20)       (12,136)           10            92,897
                                                      ------------ ------------  ------------  ------------  ----------------
    Net cash (used) in operating activities            (717,250)     (243,463)      (360,511)     (105,038)      (15,477,558)

Cash flows from investing activities:
Disposal of property and equipment                      222,296            -             -             -             222,296
Purchase of property and equipment                          -              -             -             -            (279,413)
Note Receivable			                            -        (125,000)           -	       -            (125,000)
Interest Receivable                                      (5,142)       (3,225)           -          (1,667)          (14,414)
                                                      ------------ ------------  ------------  -------------  ---------------
    Net cash (used) in investing activities             217,154      (128,225)           -          (1,667)         (196,531)

Cash flows from financing activities:
 Advances to BICO                                      (377,727)   (2,724,903)      (203,290)   (1,075,833)       (7,341,253)
 Repayment of advances to BICO                          938,011     1,247,007        656,123       119,918         7,270,690
 Proceeds from issuance of common stock                     -           3,500            -             -          10,971,834
 Proceeds from issuance of common stock to BICO             -              -             -             -           4,200,000
 Proceeds from warrants exercised                           -              -             -             -             118,066
 Proceeds from treasury stock                               -              -             -             -             (35,000)
 Proceeds from Regulation S                                 -              -             -             -             288,751
 Proceeds from issuance of notes payable                    -              -             -             -             303,000
                                                   --------------  -------------- ------------- ------------  ---------------
   Net cash provided by financing activities            560,284    (1,474,396)       452,833      (955,915)       15,776,088
                                                   --------------  -------------- ------------- ------------  ---------------
   Net increase (decrease) in cash and cash equiv.       60,188    (1,846,084)        92,322    (1,062,620)          101,999
   Cash and cash equivalents at beginning of period      41,811     1,871,070          9,677     1,087,606              -
                                                   --------------  -------------- ------------- ------------  ---------------
   Cash and cash equivalents at end of period     $     101,999   $    24,986    $   101,999   $    24,986    $      101,999
                                                   ==============  ============== ============= ============  ===============

See notes to the financial statements.
</TABLE>
                    DIASENSOR.COM, INC.

         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


NOTE A - Basis of Presentation

     The accompanying financial statements of Diasensor.com,
Inc.  (the "Company") have been prepared in accordance  with
generally   accepted  accounting  principles   for   interim
financial information, and with the instructions to Form 10-
Q  and  Rule 10-O Regulation S-X.  Accordingly, they do  not
include  all  of the information and footnotes  required  by
generally   accepted  accounting  principles  for   complete
financial  statements.  In the opinion  of  management,  all
adjustments   (consisting  of  normal  recurring   accruals)
considered  necessary  for  a fair  presentation  have  been
included.   For further information, refer to the  financial
statements  and  footnotes included in the Company's  annual
report on Form 10-K for the fiscal year ended September  30,
1998.

NOTE B - Organization

      The  Company  was incorporated on July 5,  1989  as  a
wholly  owned  subsidiary  of  Biocontrol  Technology,  Inc.
(BICO).   BICO  owns 52% of the stock of the Company  as  of
June  30,  1999.   Diasensor.com is currently  developing  a
noninvasive glucose sensor (Sensor).  The sensor  would  use
electromagnetic   technology  to   measure   blood   without
requiring the user to take a blood sample.

NOTE C - Net Loss Per Common Share

      Net  loss  per common share is based on  the  weighted
average  number of outstanding common shares, which amounted
to  22,980,051 and 22,980,051 for the periods ended June 30,
1999  and  June 30, 1998, respectively. The loss  per  share
does  not include common stock equivalents since the  effect
would be anti-dilutive.

          From July 5, 1989 (inception) to June 30, 1999, net
loss per common share is based on the weighted average number
of  common shares outstanding and the number of common shares
issuable  on  the  exercise of 1,708,000 warrants  issued  in
1992;  reduced by 488,000 common shares that were assumed  to
have  been  purchased with the proceeds from the exercise  of
the  warrants  at an assumed price of $3.50 per  share.   The
inclusion  of the warrants in the loss per share  calculation
is  required  by  the  rules of the Securities  and  Exchange
Commission  relative  to the initial registration  statement,
which included the Company's financial statements through the
period  ended  March  31,  1993.  The registration  statement
became  effective July 19, 1993.  The weighted average number
of  common  shares including the effect of the conversion  of
the  warrants amounted to 19,083,045 for the period from July
5, 1989 (inception) to June 30, 1999.

NOTE D - Legal Proceedings

In 1998, the Company and its affiliates were served with
subpoenas by the U.S. Attorneys' office; the Company is
currently in the process of copying documents for production
in response to such subpoenas.  The class action suit which
names the Company as a defendant remains in the pre-trial
pleading stage pursuant to consent of all the parties.


 Management's Discussion and Analysis of Financial Condition
                       and Cash Flows


Liquidity and Capital Resources

      Cash increased from $41,811 at September 30, 1998,  to
$101,999  at  June  30, 1999.  This increase was primarily
attributable to BICO's repayment of prior advances.

Results of Operations

           There  were no research and development  expenses
during  the nine month period ended June 30, 1999  and  1998
due  to  the  agreed-upon suspension  of  the  Research  and
Development Agreement between Diasensor.com and BICO.

      General  and Administrative expenses decreased  during
the  third quarter from $141,234 for the three month  period
ended  June 30, 1998 to $(102,067) for the three month period
ended June 30, 1999 and decreased from $303,946 for the nine
month  period ended June 30, 1998 to $140,422 for  the  nine
month  period  ended  June  30,  1999.  The overall decrease
in G&A expenses, as well as the credit figure for the third
quarter, are due to repayments of debt which had already
been written off as uncollectible.  For accounting purposes,
that uncollectible expense is included in General and
Administrative expenses, so when those debts are repaid
(in this case, amounts due from BICO), the amounts are credited
to G&A.

      Other  income during the third quarter decreased  from
$13,890  for the three month period ended June 30,  1998  to
$10,988  for the three month period ended June 30, 1999  and
increased from $35,673 for the nine month period ended  June
30, 1998 to $37,394 for the nine month period ended June 30,
1999.   These fluctuations were due to the Company having
varying amounts of cash reserves to invest during the period
ending June 30, 1999 than during the period ending June 30, 1998.

                PART II -- OTHER INFORMATION

Item 1.        Legal Proceedings
               None.

Item 2.        Changes in Securities
               None.

Item 3.        Defaults Upon Senior Securities
               None.

Item 4.        Submission of Matters to a Vote of Security Holders
               None.

Item 5.        Other Information
               None.

Item 6.        Reports on Form 8-K
               None.

SIGNATURES


     Pursuant to the requirements of the Securities Exchange
Act  of 1934, the registrant has duly caused this report  to
be  signed  on its behalf by the undersigned thereunto  duly
authorized on this 13th day of August, 1999.


                              DIASENSOR.COM, INC.

                              By /s/ Fred E. Cooper
                                   Fred E. Cooper
                                   President and Director
                                   (principal executive officer,
                                   principal financial
                                   officer and principal accounting
                                   officer)






© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission